About Rejuvenate Bio
Rejuvenate Bio is a company based in San Diego (United States) founded in 2017 by Noah Davidsohn, George Church, and Daniel Oliver. Rejuvenate Bio has raised $34.05 million across 3 funding rounds from investors including KdT Ventures, Digitalis Ventures and VCapital. The company has 39 employees as of December 31, 2022. Rejuvenate Bio offers products and services including Gene Therapy Pipeline. Rejuvenate Bio operates in a competitive market with competitors including Beam Therapeutics, eGenesis, Korro Bio, Novogene Corporation and Metagenomi, among others.
- Headquarter San Diego, United States
- Employees 39 as on 31 Dec, 2022
- Founders Noah Davidsohn, George Church, Daniel Oliver
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rejuvenate Bio Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$34.05 M (USD)
in 3 rounds
-
Latest Funding Round
$19.47 M (USD), Series A
Jun 03, 2026
-
Investors
KdT Ventures
& 7 more
-
Employee Count
39
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Rejuvenate Bio
Rejuvenate Bio offers a comprehensive portfolio of products and services, including Gene Therapy Pipeline.
Develops treatments for chronic diseases via gene therapy approaches
People of Rejuvenate Bio
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Rejuvenate Bio
Rejuvenate Bio has successfully raised a total of $34.05M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $19.47 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rejuvenate Bio
Rejuvenate Bio has secured backing from 8 investors, including venture fund, angel, and institutional investors. Prominent investors backing the company include KdT Ventures, Digitalis Ventures and VCapital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are made in frontier science ventures.
|
Locked | Locked | Locked | |
|
Digitalis Ventures is engaged in health-focused investments.
|
Locked | Locked | Locked | |
|
Venture capital investment opportunities are provided for accredited investors.
|
Locked | Locked | Locked |
Investor details for Rejuvenate Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rejuvenate Bio
Investment portfolio details for Rejuvenate Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rejuvenate Bio
Detailed financials for Rejuvenate Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rejuvenate Bio Comparisons
Peer comparison for Rejuvenate Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rejuvenate Bio
Rejuvenate Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, eGenesis, Korro Bio, Novogene Corporation and Metagenomi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| Locked | Locked | Locked |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Genomic services and solutions with NGS expertise are provided.
|
|
| Locked | Locked | Locked |
Next-generation gene editing tools are developed for drug enhancement.
|
|
| Locked | Locked | Locked |
Genetic therapies for diseases are developed using prime editing technology.
|
Detailed competitors of Rejuvenate Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rejuvenate Bio
Complete news archive for Rejuvenate Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rejuvenate Bio
Rejuvenate Bio was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Rejuvenate Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Daniel Oliver is the current CEO of Rejuvenate Bio. They have also founded this company.
Rejuvenate Bio is a funded company, having raised a total of $34.05M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Rejuvenate Bio is 39.
Rejuvenate Bio was founded in 2017 and is based in San Diego, United States. A gene-editing platform is developed by the company for anti-aging therapies targeting dogs. Technology has been applied to modulate gene activity in aged mice. Plans are in place to modify two genes addressing four aging-related diseases: heart and kidney failure, obesity, and diabetes. Operations focus on biotechnology within the veterinary and longevity sectors.
Rejuvenate Bio's top competitors include eGenesis, Tessera Therapeutics and Novogene Corporation.
Rejuvenate Bio offers Gene Therapy Pipeline.
Rejuvenate Bio has 8 investors. Key investors include KdT Ventures, Digitalis Ventures, VCapital, Katherine High, and Kendall Capital Partners.